Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled Trial for Improving the Response to Lenvatinib in Patients With Drug-resistant Thyroid Cancer by Chronobiology

NCT06321120 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT06321120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06321120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled Trial for Improving the Response to Lenvatinib in Patients With Drug-resistant Thyroid Cancer by Chronobiology
Lead sponsor
Hadassah Medical Organization
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2023
Completion date
June 30, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lenvatinib treatment